Ambiq Q2 Sales Jump 90% as Edge-AI Demand Tests Chip Supply

Austin, August 11, 2026, 08:20 EDT

Second-quarter sales rose 89.7% to $33.9 million, beating the FactSet consensus by 7.6%.
The adjusted loss was $0.07 a share, versus the $0.26 loss analysts expected.
Third-quarter sales guidance of $36 million to $37 million also topped Wall Street’s view.
Management expects second-half sales to more than double, but chip supply is tight.

Ambiq Micro, Inc. NYSE:AMBQ delivered a clean beat-and-raise quarter before Tuesday’s open. The edge-AI chipmaker paired 90% sales growth with a smaller loss. Its shares rose 6% to $67.75 in premarket trading.

The numbers shift the investor debate. Demand is no longer the main uncertainty. Supply and conversion now matter more.

Ambiq beat FactSet’s second-quarter sales estimate by $2.4 million. Its adjusted loss was 19 cents narrower than expected. The midpoint of third-quarter sales guidance was 7.4% above consensus.

Measure	Company result or guide	FactSet consensus	Difference
Q2 net sales	$33.9 million	$31.5 million	7.6% above
Q2 adjusted EPS	-$0.07	-$0.26	$0.19 better
Q3 sales, midpoint	$36.5 million	$34.0 million	7.4% above
Q3 adjusted EPS, midpoint	-$0.16	-$0.27	$0.11 better

The quarter also showed better operating leverage. GAAP gross margin widened 4.9 percentage points from a year earlier. The non-GAAP loss fell by $4.1 million.

Quarterly measure	Q2 2026	Q1 2026	Q2 2025
Net sales	$33.901 million	$25.060 million	$17.873 million
GAAP gross margin	45.0%	43.5%	40.1%
GAAP net loss	$7.115 million	$10.171 million	$8.496 million
Non-GAAP net loss	$1.772 million	$5.046 million	$5.862 million

Chief Executive Fumihide Esaka put the constraint plainly. “Given the rapid acceleration in AI demand, we and the broader semiconductor industry are facing supply constraints.” The company still expects second-half sales to more than double from last year. Ambiq

That makes the June stock offering more relevant than simple dilution math. Ambiq raised about $168 million after fees. Cash reached $366.8 million at June 30.

Working capital rose with the order book. Inventory increased 73% in six months. Receivables more than doubled, while first-half operating cash use almost doubled. Those movements suggest a faster build, not yet a self-funding one.

Balance-sheet or cash-flow measure	June 30, 2026	Comparison period	Change
Cash and equivalents	$366.774 million	$140.275 million at Dec. 31	+161.5%
Inventory	$29.365 million	$16.937 million at Dec. 31	+73.4%
Accounts receivable	$17.528 million	$7.286 million at Dec. 31	+140.6%
Six-month operating cash use	$20.678 million	$10.549 million a year earlier	+96.0%

The growth pattern began before this quarter. In May, Needham analyst Quinn Bolton said, “The company is seeing uplift across both units and ASPs, though unit growth remains the larger driver.” Ambiq’s first-quarter sales had risen 59%. Investor’s Business Daily

Wall Street’s targets show how much execution is already in question. The latest published calls span $44 to $125. The four cited recommendations all predate Tuesday’s results.

Date	Firm and analyst	Recommendation	Price target
July 14, 2026	Roth Capital — Suji Desilva	Buy	$125
May 13, 2026	UBS — Timothy Arcuri	Neutral	$70
May 12, 2026	Needham — Quinn Bolton	Buy	$70
April 21, 2026	Northland — Gus Richard	Outperform	$44

Ambiq remains young as a public company. It priced its July 2025 initial offering at $24. Shares later reached an intraday high of $91.61 on June 18, then retreated during a wider semiconductor selloff.

The previous week left the stock below that peak and short of key moving averages. Tuesday’s premarket gain only recovered part of the decline. The regular New York session had not opened at publication time.

Risks: Ambiq is still loss-making and depends on external manufacturing. Supply limits could delay sales. A richer product mix could also reverse, while the larger share count from the offering dilutes per-share gains.

The week ahead offers a direct test. Ambiq needs only 7.7% sequential growth to reach the third-quarter midpoint. Yet its second-half pledge requires sustained acceleration. Capacity, not demand, now sets the ceiling.

TS2 TECH • EXTENDED COVERAGE

Further analysis

Editorial insight

What led to the increase in Ambiq Micro shares following the second-quarter results?

Ambiq reported second-quarter revenue of $33.9 million, an increase of 89.7% year-over-year, surpassing Wall Street’s forecasts alongside a smaller-than-expected adjusted loss of $0.07 per share, compared with the $0.26 per share loss projected by analysts. Ambiq also gave third-quarter guidance above analyst expectations. Shares gained 6% to $67.75 ahead of the market open on Tuesday.

Which figure is key in Ambiq's forecast?

Third-quarter sales are pegged at a midpoint of $36.5 million, marking a 7.7% increase over the prior quarter and a 7.4% rise compared to the FactSet consensus. Management anticipates second-half sales will more than double year-over-year. However, gains may be capped by supply constraints.

Has Ambiq reached profitability?

No. GAAP net loss for the second quarter stood at $7.1 million. Non-GAAP loss decreased to $1.8 million, compared to $5.9 million in the same period last year. Gross margin saw an increase, while operating cash outflow for the first half almost doubled to $20.7 million.

Is Ambiq’s cash position sufficient to increase its chip supply?

Ambiq closed June holding $366.8 million in cash, bolstered by an approximately $168 million net capital raise. This provides management with resources to ensure capacity and support development efforts. However, execution risk remains. Over six months, inventory climbed 73%, while receivables increased by more than double.

What factors might alter the investment outlook next?

What counts most is whether Ambiq turns demand into shipments while maintaining margins. Investors should monitor third-quarter revenue versus the company’s $36 million to $37 million forecast, non-GAAP gross margin relative to the 46.5% to 47.5% range, and any updates on additional capacity. If supply issues lead to a miss, it would put the second-half growth promise at risk.